September 27, 2023 11:16 AM EDT
News Briefing

Théa won't buy Pro­QR's oph­thalmic as­sets; Im­muno­vant’s $130M of­fer­ing; In­ozyme to start piv­otal study in Oc­to­ber

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Pro­QR’s failed di­vesti­ture: Lab­o­ra­toires Théa scrapped plans to buy Pro­QR Ther­a­peu­tics’ late-stage oph­thalmic pipeline af­ter an­nounc­ing a deal in ear­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times